B7-H3L cell surface antigen and antibodies that bind thereto
First Claim
1. A substantially purified immunoglobulin polypeptide or an antigen binding fragment thereof, that specifically binds to an epitope of a B7-H3L protein that is expressed and exposed in its native conformation on the surface of a living cancer cell in vitro or in vivo, wherein said epitope is insufficiently expressed on the surface of a living normal cell to exhibit binding by said purified immunoglobulin polypeptide, and wherein said purified immunoglobulin polypeptide or antigen binding fragment thereof can be internalized into said cancer cell expressing B7-H3L.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.
-
Citations
7 Claims
- 1. A substantially purified immunoglobulin polypeptide or an antigen binding fragment thereof, that specifically binds to an epitope of a B7-H3L protein that is expressed and exposed in its native conformation on the surface of a living cancer cell in vitro or in vivo, wherein said epitope is insufficiently expressed on the surface of a living normal cell to exhibit binding by said purified immunoglobulin polypeptide, and wherein said purified immunoglobulin polypeptide or antigen binding fragment thereof can be internalized into said cancer cell expressing B7-H3L.
-
4. A pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that specifically binds to an epitope of B7-H3L protein that is expressed and exposed in its native conformation on the surface of a living cancer cell in vitro or in vivo, wherein said epitope is insufficiently expressed on the surface of a living normal cell to exhibit binding by said antibody, and wherein said purified antibody or antigen binding fragment thereof can be internalized into said cancer cell expressing B7-H3L;
together with a pharmaceutically acceptable carrier. - View Dependent Claims (5)
-
6. An isolated antibody comprising an antigen-binding fragment of the antibody expressed by the hybridoma having ATCC Deposit No. PTA-4217, ATCC Deposit No. PTA-4218, ATCC Deposit No. PTA-4244, or ATCC Deposit No. PTA-4245.
Specification